We had a great time at #ARVO2023 and the 2023 Retinal Cell and Gene Therapy Innovation Summit last week! Thanks to the organizers and all the old and new friends we made while sharing updates on our lead program in ABCA4 retinopathies. We look forward to seeing everyone in Seattle, WA next year! Until then, you can catch #TeamAscidian next in Los Angeles 🌴 at #ASGCT2023!

1/Our new paper, "Comparative connectomics reveals noncanonical wiring for color vision in human foveal retina", now published in @PNASNews

Welcome news after participating in a fascinating symposium on retinal connectomics at #ARVO2023

Our new paper, "Comparative connectomics reveals noncanonical wiring for color vision in human https://mathstodon.xyz/emoji/1f602.svgfoveal retina", now published in @PNASNews

Welcome news after participating in a fascinating symposium on retinal connectomics at #ARVO2023

https://www.pnas.org/doi/10.1073/pnas.2300545120

Coverage of Luxa Biotechnology & NSCI's clinical trial update in the @EmmesCRO session at #ARVO2023 by Ophthalmology Times:
https://zurl.co/QRR2
@OphthTimes
#maculardegeneration #stemcell #clinicaltrial

Today at #ARVO2023! NSCI's Nathan Boles will present "Characterization of RPE subpopulation gene expression & cell surface protein composition using #singlecell sequencing."
Session: Genomic Dissection of the Eye using 'omics & Single Cell Tech
#scRNAseq
@TakaraBioUSA
@BioLegend

NSCI is loving #ARVO2023! Great to reconnect with Dr. @JanmeetSaini who completed his PhD under Sally Temple's mentorship and is now a scientist with @Merck!

Happening today at #ARVO2023! Jeffrey Stern joins a distinguished panel to discuss Ophthalmic Cell & Gene Therapies hosted by @EmmesCRO.

Jeff co-founded both RRF & Luxa Biotech., sponsor of our Phase 1/2a clinical trial for a #StemCellTherapy to treat #maculardegeneration.

Thank you Rajesh, both for this touching post and for being such a terrific clinician and collaborator! It's especially timely as today is both the 1st day of #ARVO2023 and Jeff & Sally's wedding anniversary!
@surgeonretina
#clinicaltrial
From LinkedIn: https://zurl.co/rKUf

ARVO 2023 is on. Exhibiter area. New Orleans.

#arvo #arvo2023

Functional performance of a vibro-tactile sensory substitution device in people with profound vision loss https://eppro02.ativ.me/web/page.php?nav=false&page=IntHtml&project=ARVO23&id=3878017&nav=false&plannersession=true #ARVO2023

For ARVO 2023. My presentation on Noregen development, bench to bedside. Sunday.
https://ativsoftware.com/appinfo.php?page=IntHtml&project=ARVO23&server=eppro02.ativ.me&id=3884243 #ARVO2023

We are excited for #ARVO2023! NSCI investigator Nathan Boles will present data on retinal pigment epithelium subpopulations identified by #scRNAseq and director of translational programs Jeff Stern will share insights from our Phase1/2a clinical trial for #maculardegeneration.

Look out 👀 for Ascidian & new data on its lead program targeting ABCA4 retinopathies, including #Stargardt disease, at the 2023 Retinal Cell & Gene Therapy Innovation Summit & #ARVO2023 meeting.

Learn more 👉 https://ascidian-tx.com/press-releases/

Busting out Ivan Schwab’s Evolution’s Witness How Eyes Evolved to re-read before the next ⁦ARVO⁩ meeting where Ivan is delivering the closing keynote. #ARVO2023

RT @ARVOinfo
It's time! Today is the deadline to submit your #ARVO2023 abstract or SIG proposal. Join @ARVOinfo in New Orleans. Submit now: https://bit.ly/2yNlNDd #ophthalmology #visionresearch